eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
6/2006
vol. 44
 
Share:
Share:
more
 
 
abstract:

Review paper
The latest recommendations for the management of ankylosing spondylitis

Ewa Stanisławska-Biernat

Reumatologia 2006; 44, 6: 330–334
Online publish date: 2006/12/15
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Ankylosing spondylitis (AS) is a chronic inflammatory disease that leads to loss of function and disability in patients. AS is responsible for significant direct and indirect socioeconomic costs. Few studies have been performed on the treatment of patients with AS with disease-modifying antirheumatic drugs, none of which have proved clearly effective in axial disease. In the last few years the results of randomised controlled trials have raised good evidence that TNF-α blockade is very effective in AS and other spondyloarthropathies. Recently published guidelines for treatment of AS are discussed. There is a need for safety and socioeconomic data for long-term treatment with biologicals.
keywords:

ankylosing spondylitis, treatment, biologic treatment, anti-TNF



Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe